Structure Encountered
Neutrolis
Develops DNASE1L3-based enzyme therapies targeting NETs in autoimmune disease
NTR-1011 is the first drug designed to dismantle neutrophil extracellular traps — and early safety data just cleared the way for lupus and RA patients.
SIGNAL·CLINICAL PULSE·SCORE 82·02 APR 2026 · 20:19 UTC
● CAPTURE — IMAGE INCOMINGFRAME 01 / 01
STRUCT. / NEUTROLIS
/ Cambridge, MA, United States
CAPT. / 02.04.26 20:19:18Z
SIGNAL / 82 / 100
Image relayed by The Biotech Voyager during pass over structure Neutrolis. Resolution as transmitted.
001Vital Statistics
DATA LOCKED
Designation
Neutrolis
Coordinates
Cambridge, MA, United States
Stage
Phase1
Type
Therapeutics
Modalities
enzyme replacement · protein therapeutic
Therapeutic area
Autoimmune · Immunology · Rheumatology
003Architecture
AWAITING ENRICHMENT
Target class · differentiator · lead asset · pipeline depth populate once the writer fills these fields on this row.
004Voyager Assessment
STRUCTURE PROFILE
Neutrolis, Inc. is a private, clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, founded in 2017. The company is pioneering a new class of rapid-acting, non-immunosuppressive therapies that directly target Neutrophil Extracellular Traps (NETs) — web-like structures implicated in tissue damage and chronic inflammation in autoimmune disease. Its proprietary exDNASE™ platform powers the development of DNASE1L3-based enzyme analogs designed to disassemble pathogenic NETs. The lead asset, NTR-1011, is a first-in-class DNASE1L3 fusion protein optimized for subcutaneous delivery. In April 2026, Neutrolis announced positive Phase 1a results from its LIBERATE-I trial, demonstrating a favorable safety profile, predictable pharmacokinetics, and no immunogenicity. Phase 1b trials in patients with moderate-to-severe systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are planned for mid-2026. The company remains an active, independent entity.
005Tags
HOUSTON CLASSIFIED
Clinical PulseNTR-1011NETsautoimmunelupusfirst-in-class
— End of transmission —This signal was received and processed by The Biotech Voyager and HOUSTON. Transmissions are auto-generated from public sources and platform telemetry. They are not edited for prose. For human analysis and connection to other signals, watch the Tuesday or Thursday mission broadcast aboard the [SHIP]. Field notes — long-form synthesis from the crew — are archived separately.